Genovis AB - ESG Rating & Company Profile powered by AI
This webpage contains a zero-cost Environmental, Social and Governance analysis covering Genovis AB. This assessment of Genovis AB employs data from across the web and also from public disclosures by Genovis AB. This ESG rating includes seventeen United Nations Sustainable Development Goals including: 'Quality Education', 'Responsible Production & Consumption' and 'Life below Water'.
Genovis AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.5; made up of an environmental score of 8.0, social score of 3.2 and governance score of 5.3.
5.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 808 | Tilray Inc | 5.6 | High |
| 808 | Y-mAbs Therapeutics Inc | 5.6 | High |
| 835 | Genovis AB | 5.5 | High |
| 835 | Animalcare Group PLC | 5.5 | High |
| 835 | Bafna Pharmaceuticals Ltd | 5.5 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Genovis AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Genovis AB disclose current and historical energy intensity?
Sign up for free to unlockDoes Genovis AB report the average age of the workforce?
Sign up for free to unlockDoes Genovis AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Genovis AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes Genovis AB disclose cybersecurity risks?
Sign up for free to unlockDoes Genovis AB offer flexible work?
Sign up for free to unlockDoes Genovis AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Genovis AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Genovis AB conduct supply chain audits?
Sign up for free to unlockDoes Genovis AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Genovis AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes Genovis AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes Genovis AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Genovis AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Genovis AB disclose water use targets?
Sign up for free to unlockDoes Genovis AB have careers partnerships with academic institutions?
Sign up for free to unlockDid Genovis AB have a product recall in the last two years?
Sign up for free to unlockDoes Genovis AB disclose incidents of discrimination?
Sign up for free to unlockDoes Genovis AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Genovis AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Genovis AB disclose parental leave metrics?
Sign up for free to unlockDoes Genovis AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Genovis AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Genovis AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes Genovis AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Genovis AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Genovis AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Genovis AB involved in embryonic stem cell research?
Sign up for free to unlockDoes Genovis AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Genovis AB disclose its waste policy?
Sign up for free to unlockDoes Genovis AB report according to TCFD requirements?
Sign up for free to unlockDoes Genovis AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Genovis AB disclose energy use targets?
Sign up for free to unlockDoes Genovis AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Genovis AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Genovis AB
These potential risks are based on the size, segment and geographies of the company.
Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.